Unicycive Therapeutics

Research only

UNCY · Tracked drugs and regulatory events

Tracked programs

1 program

hyperphosphatemia in chronic kidney disease patients on dialysis

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseir.unicycive.com

Sponsor describes a nanoparticle oral phosphate binder and a March 25, 2027 target after NDA resubmission.

Registry identifies an OLC tolerability study in dialysis patients sponsored by Unicycive.